BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CyDex, Inc. Announces Captisol Technology Used In Recently Launched Injection Formulation Of Antipsychotic Medication ABILIFY(R) (aripiprazole)


12/18/2006 3:49:17 PM

LENEXA, Kan., Dec. 14 /PRNewswire/ -- CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced ABILIFY® Injection, a new intramuscular form of the antipsychotic medication ABILIFY® (aripiprazole) from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., contains CyDex's Captisol Technology. ABILIFY Injection is the third drug formulation commercially available in the United States utilizing CyDex's Captisol® enabling technology. The U.S. Food and Drug Administration (FDA) approved ABILIFY Injection on September 20, 2006.

CyDex's patented Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs. In addition to injectable products, the CyDex pipeline of licensed and proprietary Captisol-enabled formulations targets a range of market segments including oral solutions and capsules, ophthalmic solutions, oral solids and inhalation.

"Bristol-Myers Squibb's and Otsuka's launch of ABILIFY Injection further demonstrates the value of Captisol in supporting line extension strategies for successful pharmaceuticals," said CyDex Chief Executive Officer John M. Seibert. "An expanding roster of CyDex pharmaceutical industry partners recognize that Captisol offers tremendous solubility advantages, and we look forward to future product launches by these partners in the years ahead."

About CyDex, Inc.

CyDex is a specialty pharmaceutical company developing proprietary products and licensing its Captisol® enabling technology. CyDex is bringing important new medications to patients by developing its own pipeline of proprietary products with advanced drug delivery solutions, and by partnering with the world's leading pharmaceutical and biotechnology companies. In addition to Geodon for Injection and Vfend IV, marketed globally by Pfizer Inc., and ABILIFY Injection marketed in the United States by Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd., CyDex has development agreements with Allergan, Inc.; Bristol-Myers Squibb; Daiichi-Asubio Pharma Co., Ltd., of Japan; Merck & Co., Inc.; Mitsubishi Corporation, of Japan; OSI Pharmaceuticals, Inc.; PTC Pharma AG, of Switzerland; TargeGen, Inc.; Taisho Pharmaceuticals of Japan and Teva Pharmaceutical Industries Ltd., of Israel. CyDex also has clinical use agreements with major pharma and biotech companies. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit http://www.cydexinc.com .

Captisol and Captisol-enabled are registered trademarks of CyDex, Inc. ABILIFY is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Geodon IM and Vfend IV are registered trademarks of Pfizer Inc.

Source: CyDex, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES